Sep 12, 2023 / 02:50PM GMT
Sean M. Laaman - Morgan Stanley, Research Division - Australian Healthcare Analyst
Good morning, everyone. I'm Sean Laaman, the Australian Healthcare Analyst here at Morgan Stanley. I'm joined on stage from ResMed, Mick Farrell, CEO; and Brett Sandercock, CFO. So welcome, gentlemen, and thank you for your time today.
Questions and Answers:
Sean M. Laaman - Morgan Stanley, Research Division - Australian Healthcare AnalystMaybe just to kick things off, pandemic, hopefully, well in the rear vision mirror by now. So how would you describe the patient volumes and the market growth compared to 2019 as a jumping off point?
Michael J. Farrell - ResMed Inc. - CEO & Chairman
Yes, good question. And -- so we're looking very much at the patient flows, and using 2019 as the base of pre-COVID, and we're seeing triple digits. So 105%, 109%, 115%, all the 140 countries that we're operating in. China, we had the most recent shutdown part, which was sort of 6, 9 months ago now, but even that's sort of flowing through the